Cash Runway Narrows to Q3 2026 as Going Concern Doubts Deepen for Protagenic Therapeutics
PTIX has more than doubled off its 52-week low of $0.128 on light trading volume (0.4× avg).
Summary
Protagenic Therapeutics' Q1 FY2027 10-Q shows cash of $565,985, enough to fund operations only until about the end of Q3 2026, with substantial doubt about its ability to continue as a going concern.
Key Events · Earnings and Guidance · PTIX
-
Cash Runway Only Through Q3 2026
Cash of $565,985 as of June 30, 2026, funds operations only until approximately the end of Q3 2026, with no committed sources of additional capital.
-
Going Concern Doubt Reaffirmed
Management states substantial doubt about the company's ability to continue as a going concern within one year after the financial statements are issued.
-
Working Capital Deficit
Working capital deficit of $362,743 as of June 30, 2026, versus working capital of $511,107 at March 31, 2026.
-
Unsolicited Partnership Inquiry
Company received an unsolicited inquiry regarding a potential partnership from an established company with expertise in neurobiology, and is broadening outreach to additional candidates.
Analysis · PTIX · Life Sciences
The 10-Q confirms a deteriorating cash position of $565,985, which funds operations only until approximately the end of Q3 2026. Management states substantial doubt about the company's ability to continue as a going concern within one year. Strategic alternatives are being explored, including a potential partnership for its lead program, but no financing is committed. This is a critical liquidity update for a micro-cap biotech already delisted from Nasdaq.
At the time of this filing, PTIX was trading at $0.35 on OTC in the Life Sciences sector, with a market capitalization of approximately $633.6K. The 52-week trading range was $0.13 to $6.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.